Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100032, China
Location status: Recruiting
NCT Number: NCT04314323
The aim of this study is to establish a nation-wide cohort study of idiopathic retroperitoneal fibrosis (IRPF) in China.
Methods: All the patients fulfilling diagnostic criteria of IRPF would be enrolled from multi-centers around China. A online database system has been established.
Endpoints: The primary endpoint is to investigate the clinical manifestations of Chinese IRPF patients; the secondary endpoints including the demographic features,laboratory characteristics, immunological tests, imaging and pathological features, in addition, the treatment and prognosis of the disease.
Interested in participating?
Request Info18 year–75 year
All sexes
Observational
Beijing, Beijing Municipality, 100032, China
Location status: Recruiting
This is a multicenter registry study of IRPF patients. Newly diagnosed IRPF patients will be recruited from all over the China. Inclusion criteria: patients with newly diagnosed IRPF will be recruited. Exclusion criteria: patients with secondary forms of retroperitoneal fibrosis or malignancy are excluded.
The data will be uploaded through the platform of Chinese Rheumatology Information Platform. Demographic data, initial symptoms, disease duration, history of allergy, and physical examination, organ involvements, laboratory findings, radiological and pathological results, as well as treatment, side effects will be recorded.
This study was approved by the Medical Ethics Committee of PUMCH (Beijing, China). All patients will sign informed consent.
Statistical Analysis: All parameters are described in the standard summary statistics, including mean, standard deviation, minimum, and maximum. All statistical analyses will be performed by SPSS.
Endpoints: The primary endpoint is to investigate the organ involvements of Chinese IRPF patients. The secondary endpoints include the demographic features,laboratory characteristics, immunological tests, imaging and pathological features, in addition, the treatment and prognosis of the disease.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 5 years
To calculate the percentage of organ involvements in at least 500 patients.
Time frame: 5 years
Time frame: 5 years
Time frame: 5 years
Time frame: 10 years
Time frame: 3 years
Contact information is provided by the study sponsor or research team.
Peking Union Medical College Hospital
Other
National Registry of Idiopathic Retroperitoneal Fibrosis in China
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05428826
Fibrosis, Idiopathic Retroperitoneal Fibrosis
Agen, France
View Trial DetailsNCT04312854
Fibrosis, Idiopathic Retroperitoneal Fibrosis
Beijing, Beijing Municipality, China
View Trial DetailsNCT04047576
Fibrosis, Pathologic Processes
Beijing, Beijing Municipality, China
View Trial DetailsNCT06065852
AH Amyloidosis, AHL Amyloidosis
Bristol, South West, United Kingdom
View Trial Details